Pemetrexed in advanced non-small-cell lung cancer

Bibliography

• Garcia M, Jemal A, Ward E, Global Cancer Facts & Figures 2007. Available from: http://www.cancer.org/downloads/STT/Global_Facts_and_Figures_2007_rev2.pdf [Last accessed March 2010]
   Google Scholar
• Jemal A, Siegel R, Ward E, Cancer Statistics, 2009. CA Cancer J Clin 2009;59:225-49
   PubMed Web of Science ®Google Scholar
• Horner M, Ries L, Krapcho M, Neyman N, editors. SEER Cancer Statistics Review, 1975-2006. Available from: http://seer.cancer.gov/csr/1975_2006/ [Last accessed 7 November 2009]
   Google Scholar
• Yang P, Allen MS, Aubry MC, Clinical features of 5,628 primary lung cancer patients. Chest 2005;128:452-62
   PubMed Web of Science ®Google Scholar
• NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-25
   PubMed Web of Science ®Google Scholar
• Azzoli CG, Baker S Jr, Temin S, American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage i.v. non-small-cell lung cancer. J Clin Oncol 2009;27:6251-66
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, De Marinis F, Rinaldi M, Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-91
   PubMed Web of Science ®Google Scholar
• Fossella F, Pereira JR, von Pawel J, Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. Jf Clin Oncol 2003;21:3016-24
   PubMed Web of Science ®Google Scholar
• Noble J, Ellis PM, Mackay JA, Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2006;1:1042-58
   PubMed Web of Science ®Google Scholar
• Zheng Z, Chen T, Li X, DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356:800-8
   PubMed Web of Science ®Google Scholar
• Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-80
   PubMed Web of Science ®Google Scholar
• Bailey LB, Gregory JF III. Folate metabolism and requirements. J Nutr 1999;129:779-82
   PubMed Web of Science ®Google Scholar
• Saif MW, Chu E. Antimetabolites. In: DeVita VT Jr, Rosenberg AE, Lawrence TS, editors. Cancer: Principles & Practice of Oncology, 8th edition. Philadelphia: Lippincott, Williams & Wilkins, 2008. p. 427-36
   Google Scholar
• Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007;6:404-17
   PubMed Web of Science ®Google Scholar
• Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 1948;238:787-93
   PubMed Web of Science ®Google Scholar
• Calvert AH, Walling JM. Clinical studies with MTA. Brit J Cancer 1998;78(Suppl 3):35-40
   Google Scholar
• Shih C, Chen VJ, Gossett LS, LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-23
   PubMed Web of Science ®Google Scholar
• Mendelsohn LG, Shih C, Chen VJ, Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 1999;26:42-7
   PubMed Web of Science ®Google Scholar
• Schultz RM, Patel VF, Worzalla JF, Shih C. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 1999;19:437-43
   PubMed Web of Science ®Google Scholar
• Racanelli AC, Rothbart SB, Heyer CL, Moran RG. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res 2009;69:5467-74
   PubMed Web of Science ®Google Scholar
• Hanauske AR, Chen V, Paoletti P, Niyikiza C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 2001;6:363-73
   PubMed Web of Science ®Google Scholar
• Rinaldi DA, Burris HA, Dorr FA, Initial Phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 1995;13:2842-50
   PubMed Web of Science ®Google Scholar
• McDonald AC, Vasey PA, Adams L, A Phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res 1998;4:605-10
   PubMed Web of Science ®Google Scholar
• Rinaldi DA, Kuhn JG, Burris HA, A Phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 1999;44:372-80
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Kudoh S, Matsui K, A Phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. Brit J Cancer 2006;95:677-82
   PubMedGoogle Scholar
• Takimoto CH, Hammond-Thelin LA, Latz JE, Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin Cancer Res 2007;13:2675-83
   PubMed Web of Science ®Google Scholar
• Rusthoven JJ, Eisenhauer E, Butts C, Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a Phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999;17:1194-9
   PubMed Web of Science ®Google Scholar
• Manegold C, Gatzemeier U, von Pawel J, Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter Phase II trial. Ann Oncol 2000;11:435-40
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Arnold A, Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 2001;92:595-600
   PubMed Web of Science ®Google Scholar
• Clarke SJ, Abratt R, Goedhals L, Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 2002;13:737-41
   PubMed Web of Science ®Google Scholar
• Smit EF, Mattson K, von Pawel J, ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a Phase II study. Ann Oncol 2003;14:455-60
   PubMed Web of Science ®Google Scholar
• Niyikiza C, Baker SD, Seitz DE, Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1:545-52
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Shin D-M, Kindler HL, Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21:1556-61
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Takimoto CH, Latz JE, Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer. Clin Cancer Res 2006;12:536-42
   PubMed Web of Science ®Google Scholar
• Mita AC, Sweeney CJ, Baker SD, Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 2006;24:552-62
   PubMed Web of Science ®Google Scholar
• Shvartsbeyn M, Edelman MJ. Pemetrexed-induced typhlitis in non-small cell lung cancer. J Thorac Oncol 2008;3:1188-90
   PubMedGoogle Scholar
• Cripps C, Burnell M, Jolivet J, Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann Oncol 1999;10:1175-9
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV, Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R, Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103
   PubMed Web of Science ®Google Scholar
• Weiss GJ, Langer C, Rosell R, Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized Phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:4405-11
   PubMed Web of Science ®Google Scholar
• Bearz A, Garassino I, Cavina R, Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study. Lung Cancer 2008;60:240-5
   PubMedGoogle Scholar
• Lee H-Y, Ahn M-J, Park YH, Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial. Lung Cancer 2009;66:338-43
   Google Scholar
• Ohe Y, Ichinose Y, Nakagawa K, Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008;14:4206-12
   PubMed Web of Science ®Google Scholar
• Cullen MH, Zatloukal P, Sorenson S, A randomized Phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 2008;19:939-45
   PubMed Web of Science ®Google Scholar
• Smit EF, Burgers SA, Biesma B, Randomized Phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009;27:2038-45
   PubMed Web of Science ®Google Scholar
• Zinner RG, Fossella FV, Gladish GW, Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 2005;104:2449-56
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Kortsik C, Dark GG, Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, Phase II trial. Clin Cancer Res 2005;11:690-6
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Dimitroulis J, Toubis M, Pemetrexed combined with paclitaxel in patients with advanced or metastatic non-small-cell lung cancer: a Phase I-II trial. Lung Cancer 2007;57:66-71
   PubMedGoogle Scholar
• Clarke SJ, Boyer MJ, Millward M, A Phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer 2005;49:401-12
   PubMed Web of Science ®Google Scholar
• Monnerat C, Le Chevalier T, Kelly K, Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin Cancer Res 2004;10:5439-46
   PubMed Web of Science ®Google Scholar
• Ma CX, Nair S, Thomas S, Randomized Phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5929-37
   PubMed Web of Science ®Google Scholar
• Treat J, Bonomi P, McCleod M, Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a Phase II trial. Lung Cancer 2006;53:77-83
   PubMedGoogle Scholar
• West HL, Wakelee HA, Perry MC, Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a Phase II clinical trial. Ann Oncol 2009;20:850-6
   PubMedGoogle Scholar
• Gridelli C, Kaukel E, Gregorc V, Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, Phase II trial. J Thorac Oncol 2007;2:221-9
   PubMed Web of Science ®Google Scholar
• Dudek AZ, Larson T, McCleod MJ, Phase I/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer. J Thorac Oncol 2008;3:394-9
   Google Scholar
• Blakely LJ, Schwartzberg L, Keaton M, A Phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer. Lung Cancer 2009;66:97-102
   Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51
   PubMed Web of Science ®Google Scholar
• Gronberg BH, Bremnes RM, Flotten O, Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217-24
   PubMed Web of Science ®Google Scholar
• Tiseo M, Bartolotti M, Gelsomino F, Ardizzoni A. First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype. Expert Rev Anticancer 2009;9:425-35
   PubMed Web of Science ®Google Scholar
• Selvaggi G, Scagliotti GV. Histologic subtype in NSCLC: does it matter? Oncology 2009;23:1133-40
   Google Scholar
• Peterson P, Park K, Fossella F, Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a Phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). EJC Suppl 2007;5:363-4
   Google Scholar
• Scagliotti G, Hanna N, Fossella F, The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009;14:253-63
   PubMed Web of Science ®Google Scholar
• Lurje G, Manegold PC, Ning Y, Thymidylate synthase gene variations: predictive and prognostic markers. Mol Cancer Ther 2009;8:1000-7
   Google Scholar
• Nakagawa T, Otake Y, Yanagihara K, Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC). Lung Cancer 2004;43:145-9
   PubMedGoogle Scholar
• Nakagawa T, Tanaka F, Otake Y, Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung. Lung Cancer 2002;35:165-70
   PubMed Web of Science ®Google Scholar
• Shintani Y, Ohta M, Hirabayashi H, New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer 2003;104:790-5
   PubMedGoogle Scholar
• Ceppi P, Volante M, Saviozzi S, Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107:1589-96
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Mey V, Nannizzi S, Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005;68:110-18
   PubMed Web of Science ®Google Scholar
• Schiller JH, Ramalingam SS. Duration of chemotherapy for metastatic non-small-cell lung cancer: more may be better after all. J Clin Oncol 2009;27:3265-7
   Google Scholar
• Grossi F, Aita M, Follador A, Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist 2007;12:451-64
   PubMed Web of Science ®Google Scholar
• Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 2009;27:3277-83
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Brodowicz T, Zielinski C, Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, Phase III study. Lancet 2009;374:1432-40
   PubMed Web of Science ®Google Scholar
• US Food and Drug Adminstration Center for Drug Evaluation and Research. Alimta. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021462s018s021s022lbl.pdf [Last accessed November 2009]
   Google Scholar
• European Medicines Agency. Summary of Product Characteristics. Alimta. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/alimta/alimta.htm [Last accessed November 2009]
   Google Scholar
• Adjei AA, Mandrekar SJ, Dy GK, Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG Study N0426. J Clin Oncol 2009.23.6406
   Google Scholar
• Patel JD, Hensing TA, Rademaker A, Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009;27:3284-9
   PubMed Web of Science ®Google Scholar
• A Phase II trial of carboplatin, bevacizumab and pemetrexed in advanced non-small cell lung cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00614822 [Last accessed January 2010]
   Google Scholar
• Pemetrexed plus bevacizumab in pretreated, advanced or metastatic non small cell lung cancer (NSCLC). Available from: http://clinicaltrials.gov/ct2/show/NCT00741221 [Last accessed January 2010]
   Google Scholar
• Patel JD, Bonomi P, Socinski MA, Treatment rationale and study design for the pointbreak study: a randomized, open-label Phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2009;10:252-6
   PubMed Web of Science ®Google Scholar
• A study of tarceva (erlotinib) and standard of care chemotherapy in patients with advanced, recurrent, or metastatic non-small cell lung cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00556322 [Last accessed November 2009]
   Google Scholar
• Trial of pemetrexed versus erlotinib in pretreated patients with non small cell lung cancer (NSCLC). Available from: http://clinicaltrials.gov/ct2/show/NCT00440414 [Last accessed November 2009]
   Google Scholar
• A Phase II study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment in patients with nonsquamous NSCLC. Available from: http://clinicaltrials.gov/ct2/show/NCT00447057 [Last accessed January 2010]
   Google Scholar
• Stinchcombe TE, West HL. Maintenance therapy in non-small-cell lung cancer. Lancet 2009;374:1398-400
   Google Scholar
• Fidias PM, Dakhil SR, Lyss AP, Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591-8
   PubMed Web of Science ®Google Scholar
• A study of induction and maintenance treatment of advanced non-squamous non small cell lung cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00789373 [Last accessed November 2009]
   Google Scholar
• Study of patients with advanced non-small cell lung cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00948675 [Last accessed January 2010]
   Google Scholar
• Ciuleanu T, Brodowicz T, Zielinski C, Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, Phase III study. Lancet 2009;374:1432-40
   PubMed Web of Science ®Google Scholar
• Kubota K, Niho S, Enatsu S, Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase ii study. J Thorac Oncol 2009;4(12):1530-6
   Google Scholar
• Trial of poor performance status patients (ToPPS). Available from: http://clinicaltrials.gov/ct2/show/NCT00892710 [Last accessed March 2010]
   Google Scholar
• Pemetrexed, carboplatin, and bevacizumab as first-line therapy in treating older patients with stage IIIB or stage IV non-small cell lung cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00798603 [Last accessed March 2010]
   Google Scholar